ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

vamikibart

Also written as “Vamikibart”, “RO7200220” and “EBI-031”.

Its studies are mostly in Macular Edema, led by 2 companies.

Drug pageVamikibart: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Dec 6, 20226 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Rocheits history only50 open or runningphase 3since Dec 6, 2022Dec 8, 2021none ahead
Eleven Biotherapeuticsits history only10 open or runningphase 1since Jul 19, 2016Jul 19, 2016none ahead
  • Named in Hoffmann-La Roche’s own pipeline as RG6179 vamikibart, phase 4, as of Oct 22, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jul 19, 2016First study: phase 1 study in Diabetic Macular EdemaNew to Eleven BiotherapeuticsEleven Biotherapeutics · NCT02842541
  2. Dec 8, 2021Hoffmann-La Roche’s first studies: 2 phase 2 studies in Diabetic Macular EdemaNew to Hoffmann-La RocheHoffmann-La Roche · NCT05151744, NCT05151731
  3. Dec 6, 20222 phase 3 studies in Uveitic Macular EdemaHoffmann-La Roche · NCT05642325, NCT05642312
  4. Jan 19, 2023Named vamikibartINNProposed as its International Nonproprietary Name in WHO's List 128 · before, RO7200220, EBI-031
  5. Jan 8, 2025Phase 1 study in Diabetic Macular EdemaHoffmann-La Roche · NCT06771271 · 85 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06771271Diabetic Macular Edema · United States1CompletedHoffmann-La RocheNov 13, 202385
NCT05642325Uveitic Macular Edema · United States, Argentina, Australia and more3CompletedHoffmann-La RocheMay 7, 2025256
NCT05642312Uveitic Macular Edema · United States, Austria, Brazil and more3CompletedHoffmann-La RocheDec 9, 2024245
NCT05151744Diabetic Macular Edema · United States, Argentina, Canada and more2CompletedHoffmann-La RocheApr 17, 2024187
NCT05151731Diabetic Macular Edema · United States, Argentina, Canada and more2CompletedHoffmann-La RocheNov 6, 2024394
NCT02842541Diabetic Macular Edema1WithdrawnEleven BiotherapeuticsOct 20170

How it is read

Names in the registry

  • “Vamikibart”, 4 entries
  • “RO7200220”, 1 entry
  • “EBI-031”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.